ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1209

Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis

Jia Shi1, Alexander Carpenter2, Christopher Wong2, Qian Wang3, Christian Lood4 and Susan Shenoi5, 1University of Washington, Seattle, WA, 2Division of Rheumatology, Seattle Children's Hospital and Research Center, Seattle, 3Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), 4University of Washington, Division of Rheumatology, Seattle, 5Seattle Children's Hospital and Research Center, Mercer Island, WA

Meeting: ACR Convergence 2025

Keywords: dermatomyositis, Muscle Function, Muscle strength

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: To evaluate the measurement properties of functional performance measures (FPMs)—broad jump (BJ) and 10-meter run (10MR)—for assessing muscle function and disease activity in children with juvenile dermatomyositis (JDM), and to assess their added value alongside conventional clinical tools.

Methods: This longitudinal cohort study included 39 children with JDM. BJ and 10MR were assessed alongside standard clinical scores. Construct validity and responsiveness were assessed through cross-sectional and longitudinal analyses (linear mixed-effects models, LMMs).

Results: FPMs correlated significantly with established disease activity and muscle function measures (Figure 1). While 10MR and BJ demonstrated moderate responsiveness (standardized response mean = -0.56 and 0.31, respectively), longitudinal analyses (Figure 2) confirmed that changes in FPMs closely tracked with improvements in Childhood Myositis Assessment Scale (CMAS) and manual muscle testing (MMT8) over time. Within the clinically inactive disease (CID) group, functional heterogeneity was evident (Figure 3A). Cluster analysis based on CMAS and MMT8 identified a subgroup with relatively low strength scores and poor FPM performance (Figures 3B-C), while a more comprehensive four-variable clustering using BJ, 10MR, CMAS, and MMT8 further stratified CID patients into three distinct phenotypes (Figure 3D). Notably, one subgroup exhibited high CMAS/MMT8 scores but reduced FPMs, suggesting residual functional impairment not captured by traditional assessments. Low internal consistency (Cronbach’s α =0.44) further suggested that FPMs capture distinct dimensions of muscle function beyond CMAS/MMT8.

Conclusion: FPMs are quick, non-invasive, and clinically feasible tools that demonstrate good measurement properties. By capturing dynamic aspects of muscle function overlooked by CMAS and MMT8, FPMs may enhance clinical assessment and support individualized management in JDM.

Supporting image 1Figure 1. Relationship between FPMs and disease activity scores in JDM.

(A-C) Correlation of baseline FPMs (BJ and 10MR) with PGA Muscle (A-B) and CMAS (C). (D-F) Relationship between broad jump and disease activity scores (PGA Muscle, MMT8, and CMAS) across all follow-up data. (G-J) Relationship between the 10-meter run and disease activity scores (PGA, PGA Muscle, MMT8, and CMAS) across all follow-up data. The red line represents the linear regression model fitted to the data, with the shaded area indicating the 95% confidence interval. The regression coefficient (β) and p-value are annotated on the plots. Statistical analyses were performed using Spearman correlation (A-C) and LMM (D-J).

Supporting image 2Figure 2. Change in FPMs and disease activity scores between follow-up visits in JDM. (A-B) Relationship between changes in BJ and changes in disease activity scores (ΔCMAS and ΔMMT8, respectively) across all follow-up data. (C-D) Relationship between changes in 10MR and changes in disease activity scores (ΔCMAS and ΔMMT8, respectively) across all follow-up data. The red line represents the linear regression model fitted to the data, with the shaded area indicating the 95% confidence interval. The regression coefficient (β) and p-value are annotated on the plots. Statistical analyses were performed using LMM.

Supporting image 3Figure 3. Evaluation of CMAS, MMT8 and functional performances in patients with JDM in clinically inactive disease (CID).

(A) Heatmap depicting two patient clusters within the CID group, based on CMAS and MMT8 scores. (B) Comparisons of BJ and 10MR performance between Cluster 1 and Cluster 2. (C) Comparisons of 10MR and BJ performance between high and low CMAS groups, as well as high and low MMT8 groups, in CID patients across all follow-up data. (D) Heatmap depicting three patient clusters within the CID group, based on CMAS, MMT8 scores, BJ and 10MR (inverted). Statistical analyses were performed using the LMM and Mann-Whitney U test with * p < 0.05 and ** p < 0.01.


Disclosures: J. Shi: None; A. Carpenter: None; C. Wong: None; Q. Wang: None; C. Lood: Archon, 5, Boehringer-Ingelheim, 5, Citryll, 2, Gilead Sciences, 5, Neutrolis, 5, Pfizer, 5, Redd Pharma, 1, 2, 5, 11; S. Shenoi: AbbVie/Abbott, 2, Pfizer, 2, sobi, 2.

To cite this abstract in AMA style:

Shi J, Carpenter A, Wong C, Wang Q, Lood C, Shenoi S. Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/beyond-muscle-strength-functional-performance-measures-enhance-assessment-of-disease-activity-in-juvenile-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/beyond-muscle-strength-functional-performance-measures-enhance-assessment-of-disease-activity-in-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology